Categories Analysis, Retail

Beyond Meat’s stock swings high and low

True to its volatile nature, shares of Beyond Meat (NASDAQ: BYND) have been swinging between high and low this week. After soaring over 12% on Tuesday and gaining around 5% at market open on Wednesday, the stock has been fluctuating and is currently down 2% in afternoon trade.

Beyond Meat has been getting attention this week thanks to its rival Impossible Foods, which rolled out new products and also withdrew from a supply deal with McDonald’s (NYSE: MCD) due to inadequate production capacity.

(Image for representation only/Photo by amirali mirhashemian on Unsplash)

Some analysts believe the exit of Impossible Foods from the McDonald’s deal creates an opportunity for Beyond Meat. McDonald’s is already testing a plant-based burger in select locations in Canada and has now expanded this trial to 52 restaurants.

Although Beyond Meat has previously faced production capacity issues, the company has scaled its production levels significantly both domestically and internationally to meet its increasing demand. It already has several partnerships in place with restaurants and fast food chains for its products.

The company believes its efforts in innovation and marketing will help drive revenues going forward. The increasing shift towards vegetarian and vegan diets and the growing demand for plant-based foods is expected to benefit the company’s topline going forward.

The majority of analysts have rated the stock as Hold and it has an average price target of $112.91, which represents an upside of 36% from the current price.

In its most recent quarter, Beyond Meat achieved profitability and exceeded expectations on both the top and bottom line results. Revenues nearly tripled year-over-year to $92 million while EPS totaled $0.06.

Beyond Meat will report its fourth quarter 2019 earnings results on January 27. Analysts have forecast earnings of $0.01 per share on revenue of $76.3 million.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top